{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:17Z","timestamp":1790765237925,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug-resistant tuberculosis (DR-TB) management is often linked with a higher rate of adverse drug reactions (ADRs) needing effective and timely management of these ADRs, which, if left untreated, may result in a higher rate of loss to follow-up of drug-resistant patients.<\/jats:p><jats:p><jats:bold>Study objective:<\/jats:bold> The study was aimed at prospectively identifying the nature, frequency, suspected drugs, and management approaches for ADRs along with risk factors of ADRs occurrence among DR-TB patients at Nishtar Medical University, Hospital, Multan, Pakistan.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold> The prospective study included all the DR-TB patients enrolled for treatment from January 2016 to May 2017 at the study site<jats:bold>.<\/jats:bold> Patients were evaluated for the treatment-induced ADRs as per standard criteria of the National Tuberculosis Program, Pakistan. Multivariate logistic regression was used to assess the independent variables associated with the occurrence of ADRs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Out of 271 DR-TB patients included in the final analysis, it was observed that 55 patients (20.3%) experienced at least three ADRs. A total of 50 (18.5%) patients experienced zero adverse effects, while 15 (5.5%), 33 (12.2%), and 53 (19.6%) patients experienced one, two, and four ADRs, respectively. Gastrointestinal disturbances (66.7%), nervous system disorders (59.4%), and electrolyte disturbances (55.7%) remained the highest reported ADRs during therapy, followed by arthralgia (49.1%), ototoxicity (24%), pruritic reactions\/rash (12.9%), dyspnoea (12.5%), and tinnitus (8.8%). Pulmonary cavitation at the baseline visit (<jats:italic>p<\/jats:italic>-value 0.001, OR 3.419; 95% CI (1.694\u20136.902) was significantly associated with the occurrence of ADRs among DR-TB patients.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The frequency of ADRs was high among the study cohort; however, these were managed effectively. Patients with recognized risk factors for ADRs occurrence need continuous clinical management efforts.<\/jats:p>","DOI":"10.3389\/fphar.2022.883483","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T09:25:08Z","timestamp":1654161908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Asif","family":"Massud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Azhar","family":"Syed Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shafqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chiau Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer Hayat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1097\/mjt.0000000000000421","article-title":"Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients","volume":"25","author":"Ahmad","year":"2018","journal-title":"Am. J. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4236\/jtr.2015.32004","article-title":"Adverse Drug Reactions in Management of Multi Drug Resistant Tuberculosis, in Tertiary Chest institute","volume":"3","author":"Akshata","year":"","journal-title":"Jtr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4236\/jtr.2015.32004","article-title":"Adverse Drug Reactions in Management of Multi Drug Resistant Tuberculosis, in Tertiary Chest Institute","volume":"3","author":"Akshata","year":"","journal-title":"Jtr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"790718","DOI":"10.3389\/fmed.2021.790718","article-title":"Frequency and Factors Associated with Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study","volume":"8","author":"Atif","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0151321","DOI":"10.1371\/journal.pone.0151321","article-title":"Rights and Responsibilities of Tuberculosis Patients, and the Global Fund: A Qualitative Study","volume":"11","author":"Atif","year":"2016","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"790718","DOI":"10.3389\/fmed.2021.790718","article-title":"Frequency and Factors Associated with Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: a Retrospective Study","volume":"8","author":"Atif","year":"2021","journal-title":"Front. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0120161","DOI":"10.1371\/journal.pone.0120161","article-title":"Doing No Harm? Adverse Events in a Nation-wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria","volume":"10","author":"Avong","year":"2015","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0277-9536(92)90271-q","article-title":"In Search of Factors Responsible for Noncompliance Among Tuberculosis Patients in Wardha District, India","volume":"34","author":"Barnhoorn","year":"1992","journal-title":"Soc. Sci. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e93206","DOI":"10.1371\/journal.pone.0093206","article-title":"Predictors of Two Months Culture Conversion in Multidrug-Resistant Tuberculosis: Findings from a Retrospective Cohort Study","volume":"9","author":"Basit","year":"2014","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4236\/jtr.2014.23018","article-title":"Prevalence and Risk Factors of Adverse Drug Reactions Associated Multidrug Resistant Tuberculosis Treatments in Selected Treatment Centers in Addis Ababa Ethiopia","volume":"2","author":"Bezu","year":"2014","journal-title":"Jtr"},{"key":"B11","first-page":"275","article-title":"Adverse Events Related to Multidrug-Resistant Tuberculosis Treatment, Latvia, 2000-2004","volume":"14","author":"Bloss","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e73975","DOI":"10.1371\/journal.pone.0073975","article-title":"Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa","volume":"8","author":"Brust","year":"2013","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.5588\/ijtld.11.0574","article-title":"Frequency of Adverse Reactions to First- and Second-Line Anti-tuberculosis Chemotherapy in a Korean Cohort","volume":"16","author":"Carroll","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1345\/aph.1Z429","article-title":"Peripheral Neuropathy Associated with Fluoroquinolones","volume":"35","author":"Cohen","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4103\/0970-2113.217569","article-title":"Adverse Drug Reactions and Treatment Outcome Analysis of DOTS-Plus Therapy of MDR-TB Patients at District Tuberculosis centre: A Four Year Retrospective Study","volume":"34","author":"Dela","year":"2017","journal-title":"Lung India"},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1515\/dmdi.1982.4.4.289","article-title":"Drug-pyridoxal Phosphate Interactions","volume":"4","author":"Ebadi","year":"1982","journal-title":"Drug Metab. Drug Interactions"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse Drug Reactions: Definitions, Diagnosis, and Management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejcdt.2012.08.018","article-title":"Treatment Outcomes Among Patients with Multi-Drug Resistant Tuberculosis in Abbassia Chest Hospital from July 2006 to June 2010","volume":"61","author":"Elmahallawy","year":"2012","journal-title":"Egypt. J. Chest Dis. Tuberculosis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B20","volume-title":"WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update","author":"Falzon","year":"2011"},{"key":"B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse Reactions to First-Line Antituberculosis Drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.5588\/ijtld.14.0277","article-title":"'I'm Fed up': Experiences of Prior Anti-tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis and HIV","volume":"18","author":"Furin","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B23","first-page":"648","article-title":"Occurrence of Serious Adverse Effects in Patients Receiving Community-Based Therapy for Multidrug-Resistant Tuberculosis","volume":"5","author":"Furin","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4236\/jtr.2021.92008","article-title":"Prevalence of Adverse Drug Reactions to Second Line Anti Tuberculosis Drugs in Nigeria: A Cross-Sectional Study","volume":"9","author":"Ganiyu","year":"2021","journal-title":"J. Tuberculosis Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.11622\/smedj.2013097","article-title":"Paradoxical Increase in Uric Acid Level with Allopurinol Use in Pyrazinamide-Induced Hyperuricaemia","volume":"54","author":"Gerdan","year":"2013","journal-title":"Singapore Med. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0212948","DOI":"10.1371\/journal.pone.0212948","article-title":"Putting in Harm to Cure: Drug Related Adverse Events Do Not Affect Outcome of Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. Experience from a Tertiary Hospital in Italy","volume":"14","author":"Gualano","year":"2019","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.rmed.2006.01.014","article-title":"Side Effects Due to Primary Antituberculosis Drugs during the Initial Phase of Therapy in 1149 Hospitalized Patients for Tuberculosis","volume":"100","author":"G\u00fclbay","year":"2006","journal-title":"Respir. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7861\/clinmedicine.14-3-279","article-title":"Multidrug-resistant and Extensively Drug-Resistant Tuberculosis: a Review of Current Concepts and Future Challenges","volume":"14","author":"G\u00fcnther","year":"2014","journal-title":"Clin. Med. (Lond)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.ijtb.2020.09.027","article-title":"Adverse Drug Reactions & Drug Interactions in MDR-TB Patients","volume":"67","author":"Gupta","year":"2020","journal-title":"Indian J. Tuberculosis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1186\/s13104-015-1806-4","article-title":"Adverse Events in the Treatment of MDR-TB Patients within and outside the NTP in Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam","volume":"8","author":"Hoa","year":"2015","journal-title":"BMC Res. Notes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ejcdt.2016.11.002","article-title":"Pattern of Prevalence, Risk Factors and Treatment Outcomes Among Egyptian Patients with Multidrug Resistant Tuberculosis","volume":"66","author":"Ibrahim","year":"2017","journal-title":"Egypt. J. Chest Dis. Tuberculosis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5578\/tt.64054","article-title":"Occurrence of Adverse Events in Patient Receiving Community-Based Therapy for Multidrug-Resistant Tuberculosis in Pakistan","volume":"66","author":"Javaid","year":"2018","journal-title":"Tuberk Toraks"},{"key":"B33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.5588\/ijtld.15.0318","article-title":"Discordance between Patient and Clinician Reports of Adverse Reactions to MDR-TB Treatment","volume":"20","author":"Kelly","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/s0022-3999(02)00309-4","article-title":"Depression and Immune Function: central Pathways to Morbidity and Mortality","volume":"53","author":"Kiecolt-Glaser","year":"2002","journal-title":"J. Psychosom Res."},{"key":"B35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.18203\/2319-2003.ijbcp20190154","article-title":"An Observational Study to Find Out Incidence and Pattern of Adverse Drug Reactions Among Multidrug Resistant Tuberculosis Patients Treated under Revised National TB Control Program of India","volume":"8","author":"Lakhani","year":"2019","journal-title":"Int. J. Basic. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated Adverse Events in the Treatment of Multidrug-Resistant Tuberculosis: an Individual Patient Data Meta-Analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e88330","DOI":"10.1371\/journal.pone.0088330","article-title":"Are We Doing Enough to Stem the Tide of Acquired MDR-TB in Countries with High TB Burden? Results of a Mixed Method Study in Chongqing, China","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"B38","first-page":"190","article-title":"Pattern of Adverse Effects of Drugs Used to Treat Multi Drug Resistant Tuberculosis","volume":"4","author":"Masuma","year":"2018","journal-title":"ibbjorg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12879-019-3919-1","article-title":"Incidence and Predictors of Major Adverse Drug Events Among Drug-Resistant Tuberculosis Patients on Second-Line Anti-tuberculosis Treatment in Amhara Regional State Public Hospitals; Ethiopia: a Retrospective Cohort Study","volume":"19","author":"Merid","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2334-14-542","article-title":"Successful MDR-TB Treatment Regimens Including Amikacin Are Associated with High Rates of Hearing Loss","volume":"14","author":"Modongo","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e3437","DOI":"10.1097\/md.0000000000003437","article-title":"Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa","volume":"95","author":"Mouton","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5958\/0976-5506.2018.00032.3","article-title":"Prevalence and Predictors of Adverse Drug Effects with Second Line Anti-TB Drugs under Programmatic Management of Drug Resistant Tuberculosis (PMDT) Services in Amritsar District","volume":"9","author":"Nagpal","year":"2018","journal-title":"Indian. J. Public Health Res. Dev."},{"key":"B43","first-page":"1382","article-title":"Adverse Events in the Treatment of Multidrug-Resistant Tuberculosis: Results from the DOTS-Plus Initiative","volume":"8","author":"Nathanson","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1515\/jbcpp-2020-0447","article-title":"Adverse Drug Reaction and its Management in Tuberculosis Patients with Multidrug Resistance: a Retrospective Study","volume":"32","author":"Nilamsari","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"B45","volume-title":"Hand Book of DR-TB Practice","year":"2017"},{"key":"B46","volume-title":"National Guidelines for Programmatic Managment of Drug Resistant Tuberculosis (PMDT)","year":""},{"key":"B47","volume-title":"National Guidlines for the Programmatic Management of Drug-Resistant Tuberculosis (PMDT), Pakistan","year":""},{"key":"B48","volume-title":"TB and Human Rights Task Force","author":"Partnership","year":"2015"},{"key":"B49","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","article-title":"Adverse Drug Reactions in Tuberculosis and Management","volume":"66","author":"Prasad","year":"2019","journal-title":"Indian J. Tuberc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijtb.2016.01.031","article-title":"Frequency of Adverse Events Observed with Second-Line Drugs Among Patients Treated for Multidrug-Resistant Tuberculosis","volume":"63","author":"Prasad","year":"2016","journal-title":"Indian J. Tuberc."},{"key":"B78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0950268803008367","article-title":"Risk Factors for Drug Resistant Tuberculosis in Leicestershire\u2013Poor Adherence to Treatment Remains an Important Cause of Resistance","volume":"130","author":"Pritchard","year":"2003","journal-title":"Epidemiol. Infect."},{"key":"B51","volume-title":"Ageing: Gender, Social Class and Health in Pakistan","author":"Qureshi","year":"2017"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.socscimed.2004.08.024","article-title":"Perceptions of Tuberculosis Patients about Their Physical, Mental and Social Well-Being: a Field Report from South India","volume":"60","author":"Rajeswari","year":"2005","journal-title":"Soc. Sci. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.18203\/issn.2454-2156.intjscirep20150955","article-title":"Adverse Events Among Patients of Multi Drug Resistant Tuberculosis Receiving Second Line Anti TB Treatment","volume":"1","author":"Rathod","year":"2015","journal-title":"Int. J. Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40264-013-0091-1","article-title":"Adverse Events during Treatment of Drug-Resistant Tuberculosis: a Comparison between Patients with or without Human Immunodeficiency Virus Co-infection","volume":"36","author":"Sagwa","year":"2013","journal-title":"Drug Saf."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1080\/14740338.2016.1216544","article-title":"Adverse Effects of Oral Second-Line Antituberculosis Drugs in Children","volume":"15","author":"Schaaf","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40360-019-0313-y","article-title":"Nephrotoxicity and Ototoxic Symptoms of Injectable Second-Line Anti-tubercular Drugs Among Patients Treated for MDR-TB in Ethiopia: a Retrospective Cohort Study","volume":"20","author":"Shibeshi","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B57","first-page":"347","article-title":"Peripheral Neuropathy Associated with Treatment for Multidrug-Resistant Tuberculosis","volume":"7","author":"Shin","year":"2003","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B58","first-page":"1314","article-title":"Adverse Reactions Among Patients Being Treated for MDR-TB in Tomsk, Russia","volume":"11","author":"Shin","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-019-1155-4","article-title":"The Impact of Adverse Events on Health-Related Quality of Life Among Patients Receiving Treatment for Drug-Resistant Tuberculosis in Johannesburg, South Africa","volume":"17","author":"Sineke","year":"2019","journal-title":"Health Qual. Life Outcomes"},{"key":"B60","first-page":"143","article-title":"Two Years Review of Cutaneous Adverse Drug Reaction from First Line Anti-tuberculous Drugs","volume":"62","author":"Tan","year":"2007","journal-title":"Med. J. Malaysia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/h0093770","article-title":"Psychosocial Study of Tuberculosis Patients","volume":"17","author":"Tandon","year":"1980","journal-title":"Indian J. Tuberc."},{"key":"B62","doi-asserted-by":"publisher","first-page":"PA2710","DOI":"10.1183\/13993003.congress-2015.PA2710","article-title":"Peripheral Neuropathy in XDR-TB Patients on Second Line Anti-tubercular Therapy","volume":"46","author":"Tiwari","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B63","volume-title":"Cycloserine Did Not Increase Depression Incidence or Severity at Standard Dosing for MDR-TB","author":"Tornheim","year":"2021"},{"key":"B64","first-page":"1373","article-title":"Side Effects Associated with the Treatment of Multidrug-Resistant Tuberculosis","volume":"9","author":"T\u00f6r\u00fcn","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0147529","DOI":"10.1371\/journal.pone.0147529","article-title":"Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan","volume":"11","author":"Ullah","year":"2016","journal-title":"PLoS One"},{"key":"B66","volume-title":"Sample Size Calculator Version 2","year":"2017"},{"key":"B67","volume-title":"A Practical Handbook on the Pharmacovigilance of Medicines Used in the Treatment of Tuberculosis: Enhancing the Safety of the TB Patient (9789241503495 9789244503492 (Russian))","author":"Who","year":"2012"},{"key":"B68","volume-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis","author":"Who","year":""},{"key":"B69","volume-title":"Definitions and Reporting Framework for Tuberculosis \u2013 2013 Revision: Updated December 2014 and January 2020","author":"Who","year":"2013"},{"key":"B70","volume-title":"Global Tuberculosis Report 2014","author":"Who","year":""},{"key":"B79","volume-title":"Guidelines for Surveillance of Drug Resistance in Tuberculosis","author":"WHO","year":"2015"},{"key":"B71","volume-title":"Global Tuberculosis Report 2020","author":"Who","year":"2020"},{"key":"B72","volume-title":"International Drug Monitoring: The Role of National Centres, Report of a WHO Meeting [held in Geneva from 20 to 25 September 1971","author":"Who","year":"1972"},{"key":"B73","volume-title":"WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","author":"Who","year":"2019"},{"key":"B74","volume-title":"WHO Global Lists of High burden Countries for Tuberculosis (TB), TB\/HIV and Multidrug\/rifampicin-Resistant TB (MDR\/RR-TB), 2021\u20132025: Background Document","author":"Who","year":"2021"},{"key":"B75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5588\/ijtld.20.0217","article-title":"Ototoxicity Among Multidrug-Resistant TB Patients: a Systematic Review and Meta-Analysis","volume":"25","author":"Wrohan","year":"2021","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","article-title":"Adverse Events Associated with the Treatment of Multidrug-Resistant Tuberculosis: a Systematic Review and Meta-Analysis","volume":"23","author":"Wu","year":"2016","journal-title":"Am. J. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.12659\/msm.904682","article-title":"Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: an Ambispective Cohort Study","volume":"23","author":"Zhang","year":"2017","journal-title":"Med. Sci. Monit."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.883483\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:40:20Z","timestamp":1654616420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.883483\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":79,"alternative-id":["10.3389\/fphar.2022.883483"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.883483","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"article-number":"883483"}}